Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
Key claim: A phase II trial is evaluating elotuzumab, an anti-SLAMF7 monoclonal antibody, as a treatment for JAK2-mutated myelofibrosis to assess disease control and improvement in blood counts and bone marrow function.
Abstract
This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
Why this matters
Elotuzumab’s entry into JAK2-mutated myelofibrosis introduces SLAMF7-directed antibody immunotherapy — a mechanism validated in multiple myeloma but never previously tested in MPNs — into the rapidly expanding JAK2-mutant PMF therapeutic landscape. It complements other immunologic approaches in PMF (anti-PD-1 with fedratinib, anti-IL-1β canakinumab, Treg CK0804, anti-MPN TCRs, mutant-CALR antibodies) while specifically targeting the JAK2-mutated subpopulation (~50–60% of PMF), offering a mechanistically distinct alternative to mutant-selective JAK2 inhibitors (PRT12396, AJ1-11095) for the same genotype-defined niche.